[{"data":1,"prerenderedAt":35},["ShallowReactive",2],{"notifications-general-de":3,"compound-CBGV-de":4},"Wegen der Sommerferien arbeitet das Labor vom 22. Juli bis 9. August 2026 nach einem geänderten Zeitplan. Analyseergebnisse sind 7 bis 10 Tage nach Proben­eingang verfügbar. Vielen Dank für Ihr Verständnis.",{"name":5,"shortname":6,"synonyms":7,"cas":8,"molMass":9,"pubchemLink":10,"structure":11,"important":12,"synthetic":12,"compoundClass":13,"asociationImage":16,"summarySet":17,"compoundEffectSet":21},"Cannabigerivarin","CBGV","Cannabigerovarin","55824-11-8",288.431,"https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002F59444407","science\u002Fstructures\u002FCBGV_El47A5u.png",false,{"id":14,"description":15},"2","Cannabinoids","",[18],{"summaryText":19,"language":20},"\u003Cp>Cannabigerivarin (CBGV) is a derivative of cannabigerol (CBG) replacing with propyl side chain istead of pently one. Like most cannabinoids, CBGV produces no psychoactive effects when ingested or inhaled. CBGV has a potential to display analgesic (painkilling), anti-inflammatory properties and anticancer properties, but most of it will have to pe proven by clinical studies in the future. \u003C\u002Fp>",null,[22,27,31],{"effectName":23,"LiteratureReferences":26},{"effectName":24,"effectType":25},"Anti-inflamation","A_0","\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.jbc.org\u002Fcontent\u002Fearly\u002F2011\u002F10\u002F25\u002Fjbc.M111.296020\" target=\"_blank\">Modulation of L-α-lysophosphatidylinositol \u002FGPR55 MAP kinase signalling by cannabinoids\u003C\u002Fa>\u003Cbr>\u003C\u002Fp>",{"effectName":28,"LiteratureReferences":30},{"effectName":29,"effectType":25},"Anti Cancer","\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.jbc.org\u002Fcontent\u002Fearly\u002F2011\u002F10\u002F25\u002Fjbc.M111.296020\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255);\">Modulation of L-α-lysophosphatidylinositol \u002FGPR55 MAP kinase signalling by cannabinoids\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Ca href=\"http:\u002F\u002Far.iiarjournals.org\u002Fcontent\u002F33\u002F10\u002F4373.long\" target=\"_blank\">Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedules\u003C\u002Fa>\u003Cbr>\u003C\u002Fp>",{"effectName":32,"LiteratureReferences":34},{"effectName":33,"effectType":25},"Anti pain","\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.jbc.org\u002Fcontent\u002Fearly\u002F2011\u002F10\u002F25\u002Fjbc.M111.296020\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255);\">Modulation of L-α-lysophosphatidylinositol \u002FGPR55 MAP kinase signalling by cannabinoids\u003C\u002Fa>\u003Cbr>\u003C\u002Fp>",1785925845654]